{"id":166421,"date":"2025-08-22T12:07:18","date_gmt":"2025-08-22T12:07:18","guid":{"rendered":"https:\/\/www.europesays.com\/us\/166421\/"},"modified":"2025-08-22T12:07:18","modified_gmt":"2025-08-22T12:07:18","slug":"growth-hormone-benefits-kids-with-rare-genetic-condition","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/166421\/","title":{"rendered":"Growth Hormone Benefits Kids With Rare Genetic Condition"},"content":{"rendered":"<p><strong>TOPLINE:<\/strong><\/p>\n<p>A standard-dose recombinant growth hormone therapy administered for 2 years demonstrated positive effects on both growth and nutritional status in prepubertal children with <a href=\"https:\/\/emedicine.medscape.com\/article\/948786-overview\" target=\"_blank\" rel=\"noopener\">Silver-Russell syndrome<\/a>, a condition characterized by severe growth retardation and feeding difficulties. Initiating treatment before the age of 4 years optimized height gains in these patients.<\/p>\n<p><strong>METHODOLOGY:<\/strong><\/p>\n<ul>\n<li>About 90% of children with Silver-Russell syndrome have severe feeding difficulties, primarily before the age of 6 years, and nearly 70% are malnourished. Data on the effects of recombinant growth hormone, especially during the initial years of therapy, are limited.<\/li>\n<li>To address this gap, researchers conducted a retrospective single-center analysis of 77 children (including 36 girls) with no sign of puberty and molecularly confirmed Silver-Russell syndrome who initiated growth hormone therapy at a mean age of 3.7 years.<\/li>\n<li>A clinical file, including extensive clinical, radiological, and biological data; growth charts; and a detailed phenotypic description, was completed for all children; these data were retrospectively collected at the initiation of treatment, 1 year before treatment, and 1-2 years after treatment onset.<\/li>\n<li>Changes in height standard deviation score (SDS) and ideal weight-for-height (as a proxy for nutritional status) were tracked.<\/li>\n<\/ul>\n<p><strong>TAKEAWAY:<\/strong><\/p>\n<ul>\n<li>Children showed a significant improvement in height, gaining 0.8 SDS after 1 year and 1.3 SDS after 2 years of treatment, with most (71.4%) achieving normal height (above -2 SDS); girls had greater gains in both height and BMI than boys (P <\/li>\n<li>After 2 years of treatment, children who started growth hormone therapy before the age of 4 years (n = 46) achieved greater height gains than those who started therapy later (1.5 vs 1.1 SDS; P = .012).<\/li>\n<li>The ideal weight-for-height increased from a median of 80% at the initiation of therapy to 84% after 1 year and 86% after 2 years (P <\/li>\n<li>The proportion of children with weight-for-height below 75% declined after 2 years of therapy, whereas those surpassing the 85% target increased.<\/li>\n<\/ul>\n<p><strong>IN PRACTICE:<\/strong><\/p>\n<p>\u201cThe nutritional status is crucial for these children, especially during the early years of life, as there is a high risk of hypoglycemia; therefore, nutritional interventions, such as early oral feeding therapy, nutritional enrichment, and cyproheptadine for those who are severely undernourished is essential,\u201d the authors of the study wrote.<\/p>\n<p>\u201cWe show here that rGH [recombinant growth hormone] also plays a part in the nutritional intervention,\u201d they added.<\/p>\n<p><strong>SOURCE:<\/strong><\/p>\n<p>This study was led by Elo\u00efse Giabicani and Rapha\u00eblle Billette de Villemeur of the H\u00f4pital Armand Trousseau in Paris, France. It was <a href=\"https:\/\/academic.oup.com\/jcem\/advance-article-abstract\/doi\/10.1210\/clinem\/dgaf452\/8237732?redirectedFrom=fulltext\" rel=\"nofollow noopener\" target=\"_blank\">published online<\/a> on August 19, 2025, in The Journal of Clinical Endocrinology &amp; Metabolism.<\/p>\n<p><strong>LIMITATIONS:<\/strong><\/p>\n<p>This study did not discuss any limitations.<\/p>\n<p><strong>DISCLOSURES:<\/strong><\/p>\n<p>This study received funding from the Rare Disorders Reference Centre (CRESCENDO). The authors reported having no conflicts of interest.<\/p>\n<p>This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.<\/p>\n","protected":false},"excerpt":{"rendered":"TOPLINE: A standard-dose recombinant growth hormone therapy administered for 2 years demonstrated positive effects on both growth and&hellip;\n","protected":false},"author":3,"featured_media":166422,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[691,738,27095,67322,67321,4471,7667,245,16622,8833,815,8499,95662,95661,95663,95613,251,8523,27094,27093,25763,159,95664,67,132,68],"class_list":{"0":"post-166421","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-ai","9":"tag-artificial-intelligence","10":"tag-artificial-neural-networks","11":"tag-bmi","12":"tag-body-mass-index","13":"tag-child","14":"tag-childhood","15":"tag-children","16":"tag-deep-learning","17":"tag-endocrinology","18":"tag-genetics","19":"tag-genomics-genomic-medicine","20":"tag-growth-hormone","21":"tag-growth-hormone-deficiency-gh-deficiency-growth-hormone-deficiency-ghd","22":"tag-hormonal-therapy","23":"tag-hormone-therapy","24":"tag-kids","25":"tag-machine-learning","26":"tag-ml-natural-language-processing","27":"tag-npl","28":"tag-pediatrics","29":"tag-science","30":"tag-silver-russell-syndrome","31":"tag-united-states","32":"tag-unitedstates","33":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115072338746434908","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/166421","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=166421"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/166421\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/166422"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=166421"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=166421"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=166421"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}